Appendix F: Aim 2 Original Model Validation

Appendix F Table 1. Aggregate Summary Table: Original model validation performance measure

	Aggregate			ACS			HF			Population		
	Related (n=57)	Distantly related (n=101)	p-value	Related (n=13)	Distantly related (n=15)	p-value	Related (n=7)	Distantly related (n=35)	p-value	Related (n=37)	Distantly related (n=51)*	p-value
% Change in discrimination												
Validation c vs. development c	-30 (-45, -16)	-55 (-68, -40)	<0.001	-19 (-27, -9)	-29 (-44, -15)	0.135	-39 (-86, -16)	-51 (-57, -40)	0.664	-42 (-46, -23)	-67 (-80, -60)	<0.001
MBc vs. development c	-25 (-34, -9)	-29 (-40, -18)	0.098	-14 (-19, -4)	-25 (-30, -18)	0.068	-33 (-38, -6)	-25 (-35, -8)	0.764	-29 (-40, -11)	-38 (-42, -24)	0.193
Validation c vs. MBc	-11 (-25, 0)	-33 (-50, -13)	<0.001	-7 (-19, 6)	-13 (-28, 14)	0.549	-9 (-65, 67)	-31 (-43, 1)	0.500	-16 (-28, -2)	-40 (-68, -24)	<0.001
Calibration												
standardized E	0.5 (0.4, 0.7)	0.5 (0.4, 0.8)	0.500	0.3 (0.2, 0.4)	0.7 (0.4, 0.8)	0.006	0.6 (0.5, 1.1)	0.5 (0.3, 0.7)	0.295	0.6 (0.5, 0.7)	0.5 (0.4, 0.8)	0.830
standardized E90	0.8 (0.7, 1.2)	1.0 (0.6, 1.3)	0.505	0.6 (0.5, 1)	1.2 (1, 1.7)	0.072	1.2 (0.8, 1.8)	0.7 (0.5, 1.2)	0.098	0.8 (0.7, 1.2)	1.1 (1, 1.3)	0.051
Net Benefit (standardized)												
at the prevalence	0.1 (0.03, 0.2)	0.14 (0.03, 0.22)	0.261	0.25 (0.21, 0.29)	0.25 (0.12, 0.3)	0.580	0.08 (0.04, 0.12)	0.14 (0.01, 0.21)	0.303	0.06 (0.02, 0.13)	0.1 (0.02, 0.18)	0.305
% not harmful, % (n)**	26.3% (15/57)	32.7% (33/101)	0.404	69.2% (9/13)	20.0% (3/15)	0.020	42.9% (3/7)	11.4% (4/35)	0.077	8.1% (3/37)	0% (0/25)	0.266

Values in table are median (Q1, Q3) and p-values are based on non-parametric Wilcoxon two-sample tests unless otherwise indicated.

*26 distantly related validations for Population CPMs are not assessed for calibration

** Values in table are % (n) and p-values are based on chi-square test for aggregate sample and Fisher's Exact tests for stratified analyses.

References

1.   Wolff RF, Moons KGM, Riley RD, et al. PROBAST: A Tool to Assess the Risk of Bias and Applicability of Prediction Model Studies. *Ann Intern Med.* 2019;170(1):51-58.
2.   Aspirin Myocardial Infarction Study Research Group. A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. *JAMA.* 1980;243(7):661-669.
3.   Berkman LF, Blumenthal J, Burg M, et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. *JAMA.* 2003;289(23):3106-3116.
4.   Magnesium in Coronaries (MAGIC) Trial Investigators. Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: a randomised controlled trial. *Lancet (London, England).* 2002;360(9341):1189-1196.
5.   TIMI II Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. *The New England journal of medicine.* 1989;320(10):618-627.
6.   TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. *Circulation.* 1994;89(4):1545-1556.
7.   Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. *The New England journal of medicine.* 2014;370(15):1383-1392.
8.   Konstam MA, Neaton JD, Dickstein K, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. *Lancet.* 2009;374(9704):1840-1848.
9.   O'Connor CM, Whellan DJ, Lee KL, et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. *JAMA.* 2009;301(14):1439-1450.
10.   Konstam MA, Gheorghiade M, Burnett JC Jr., et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. *JAMA : the journal of the American Medical Association.* 2007;297(12):1319-1331.
11.   Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. *The New England journal of medicine.* 2005;352(3):225-237.
12.   Beta-Blocker Evaluation of Survival Trial I. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. *The New England journal of medicine.* 2001;344(22):1659-1667.
13.   Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. *The New England journal of medicine.* 1997;336(8):525-533.
14.   Investigators S, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. *The New England journal of medicine.* 1991;325(5):293-302.
15.   Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. *The New England journal of medicine.* 2008;358(24).
16.   ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA.* 2002;288(23):2981-2997.

17.	ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). *JAMA.* 2002;288(23):2998-3007.
18.	Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. *JAMA.* 2002;288(3):321-333.